2020年10月8日 · In particular, the humanized monoclonal anti ICOS-L antibody prezalumab has recently shown efficacy in the treatment of patients with systemic lupus erythematosus (SLE) in a phase Ib clinical...

Objectives: Systemic lupus erythematous (SLE) is a heterogeneous disease lacking highly effective treatment options. Here we tested if targeting both BAFF and ICOSL has superior efficacy than single target inhibition in the mouse arthritis and lupus models.

2015年4月7日 · In a new report published in Immunity, ICOS ligand (ICOSL) expression by CD11c + (also known as integrin α-X, encoded by Itgax) myeloid cells was associated with enhanced T-cell survival in the...

2022年10月1日 · Through ex vivo cocultures of Th and B cells from SLE mice or patients and in vivo SLE mouse models, we demonstrated that RAP-encapsulated ICOS/CD40L bispecific NPs selectively target SLE Th cells and potently inhibit Th–B-cell reciprocal activation by targeting dual costimulatory pathways.

2020年9月9日 · ICOS/ICOSL axis–mediated glucose incorporation and utilization were crucial for inflammatory T H subset induction by B cells, and activation of mTOR was critical for T cell glycolysis in this process.

2016年7月7日 · Our results indicate that ICOS regulates the ontogeny and homeostasis of B6.Sle1 T FH cells and influences the function of T FH cells during aberrant germinal center B cell responses. Therapies targeting the ICOS signaling pathway may offer new opportunities for the treatment of lupus and other autoimmune diseases.

AMG 570 is a bispecific molecule targeting T cell and B cell activity through inhibition of the inducible costimulator ligand (ICOSL) and the B cell activating factor (BAFF). We hypothesize that targeting both ICOSL and BAFF will be more effective than single target inhibition in SLE and other autoimmune diseases.

To investigate the level of costimulating molecules in systemic lupus erythematosus (SLE), we assessed the plasma concentrations of soluble forms of costimulatory molecules such as programmed death-1 (PD-1), B7-H1 (also called PD-L1 or CD274) and inducible costimulator ligand (ICOSL) in patients wit …

2015年9月29日 · Clinical trial of monoclonal antibody targeting ICOSL in SLE is underway. However, the expression of ICOSL and the role of ICOS/ICOSL signaling in the interactions between T cells in the pathogenesis of SLE are not well characterized. We investigate the expression and function of the ICOSL on T cells in patients with SLE

To investigate the role of ICOS/ICOSL,OX40/OX40L and CD40/CD40L in systemic lupus erythematosus (SLE), we have compared ICOS, OX40, CD40L expressions on the surface of CD4 + T cells and...